# A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

> **NCT06388707** · PHASE1,PHASE2 · RECRUITING · sponsor: **NaviFUS Corporation** · enrollment: 8 (estimated)

## Conditions studied

- Drug Resistant Epilepsy
- Epilepsy
- Seizures, Focal
- Seizure
- Seizure Disorder

## Interventions

- **DEVICE:** NaviFUS System

## Key facts

- **NCT ID:** NCT06388707
- **Lead sponsor:** NaviFUS Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-13
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06388707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06388707, "A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06388707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*